Aaron Wealth Advisors LLC Increases Holdings in AbbVie Inc. $ABBV

Aaron Wealth Advisors LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 18.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,340 shares of the company’s stock after buying an additional 3,983 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in AbbVie were worth $5,790,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after buying an additional 448,554 shares in the last quarter. Legal & General Group Plc raised its position in shares of AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after buying an additional 493,420 shares in the last quarter. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Amundi raised its position in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of AbbVie by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after buying an additional 408,426 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Down 1.1%

Shares of NYSE:ABBV opened at $206.62 on Tuesday. The company has a market capitalization of $365.35 billion, a price-to-earnings ratio of 87.55, a PEG ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm’s 50-day moving average is $221.30 and its 200 day moving average is $224.39.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent research reports. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Piper Sandler upped their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and outlets highlight AbbVie’s valuation and income appeal — calls that the shares look like a strong value play for long‑term investors given yield and discounted multiples. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Positive Sentiment: Seeking Alpha notes that while 2026 sets a high earnings bar, AbbVie’s shares remain attractive on valuation — a constructive view that can support the stock over time if guidance is met. AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
• Positive Sentiment: Comparisons with peers emphasize AbbVie’s attractive dividend profile versus Pfizer, supporting income‑focused demand for the stock. High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout
• Positive Sentiment: Analysts are watching Skyrizi and Rinvoq as the key growth drivers for Q1 immunology sales and market‑share recovery as Humira wanes — successful execution here would materially reinforce revenue trajectory. How Will Skyrizi and Rinvoq Shape AbbVie’s Q1 Immunology Sales?
• Neutral Sentiment: Sector news: two more drug firms are joining the TrumpRx pricing initiative — a broader pricing‑pressure story that could matter to big pharma if it expands, though the immediate impact on AbbVie is uncertain. Two more drug companies to officially launch on TrumpRx
• Neutral Sentiment: Miscellaneous industry piece (Regeneron/Kiniksa Arcalyst orphan‑drug coverage) is not AbbVie‑specific but contributes to wider sector investor interest in niche drug opportunities. Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
• Negative Sentiment: AbbVie lowered its Q1 and full‑year 2026 earnings outlook after taking a $744M R&D charge — a direct negative to near‑term earnings expectations and a primary reason for the share weakness. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
• Negative Sentiment: Market coverage notes the stock has underperformed peers and declined despite broader market gains — reinforcing short‑term selling pressure and investor caution. AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
• Negative Sentiment: Additional note on underperformance vs. competitors from MarketWatch — another datapoint traders use to justify reduced weight in the stock near term. AbbVie Inc. stock underperforms Monday when compared to competitors

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.